Subacute Sclerosing Panencephalitis: Impact on Public Health, Current Insights, and Future Perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative literature review without systematic review or meta-analytic methodology
PubMed 39924947 · doi:10.1002/brb3.70292
What was done
The authors conducted a literature search using PubMed and Google Scholar starting in April 2024 to summarize existing evidence on the pathogenesis, clinical staging, public health impact, and management of subacute sclerosing panencephalitis (SSPE).
What was found
No quantitative findings or effect sizes are reported in the abstract. The authors report that SSPE typically manifests approximately 10 years following measles infection, progresses across four stages from personality changes to coma, and is almost universally fatal. Reported management strategies include antiepileptic drugs, interferon combinations, ribavirin, vitamin A, and ketogenic diets, while vaccination remains the only preventive measure.
Why it matters
This paper summarizes the clinical trajectory and preventive strategies for SSPE, emphasizing the risk of resurgence following post-pandemic declines in measles immunization.
Limits
Narrative review design without systematic inclusion protocols, risk of bias assessment, or quantitative data synthesis. The abstract provides no specific case counts, effect estimates, or pooled outcomes.
Cited by
- supports Measles infection can cause brain inflammation (encephalitis).